MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Purpose: Papillary renal cell carcinomas (pRCC) are the most common nonclear cell RCC subtype. Germline mutations of the MET oncogene at 7q31 have been detected in patients with hereditary type I pRCC and in 13% of sporadic type I pRCC. Recent report of MET inhibition strengthened the role of c-Met inhibition across pRCC. Experimental Design: We collected 220 frozen samples of sporadic pRCC through the French RCC Network and quality controlled for percentage of malignant cells >70%. Gene expression was assessed on 98 pRCC using human whole-genome Agilent 8 × 60K arrays. Copy number alterations were analyzed using Agilent Human 2 × 400K and 4× 180K array for type II pRCC and comparative genomic microarray analysis method for type I pRCC. MET gene sequencing was performed on type I pRCC. Results: MET expression level was high across all pRCC. We identified copy number alterations (gain) in 46% of type II pRCC and in 81% of type I pRCC. Correlation between DNA copy number alterations and mRNA expression level was highly significant. Eleven somatic mutations of MET gene were identified amongst 51 type I pRCC (21.6%), including 4 new mutations. We validated LRRK2 cokinase as highly correlated to MET expression. Conclusion: The present report expands the role of MET activation as a potential target across all pRCC subtypes. These data support investigating MET inhibitors in pRCC in correlation with MET activation status. Clin Cancer Res; 20(13); 3411–21. ©2014 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602 · cited 1×
“More specifically, MET activation is involved in tumorigenesis,metastases through cell–cell detachment,migration, and invasiveness (14).”
BackgroundCircular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,325 · cited 1×
“These profiles were segmented with the CBS (circular binary segmentation) algorithm (22) through its implementation in the DNAcopy v1.”
MethodIdentification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M.-L., Kmiecik, T. E., Vande Woude, G. F., & Aaronson, S. A. (1991) · Science · doi:10.1126/science.1846706 · Cited by 2,236
Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,524
Schmittgen, T. D., & Zakrajsek, B. A. (2000) · Journal of Biochemical and Biophysical Methods · doi:10.1016/s0165-022x(00)00129-9 · Cited by 1,242 · cited 1×
“18S primer sequences have been previously described by Schmittgen and Zakrajsek (23).”
2004 WHO Classification of the Renal Tumors of the Adults
Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Kirkali, Z. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.035 · Cited by 893
An overview of the c-MET signaling pathway
Organ, S. L., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422556 · Cited by 875 · cited 2×
“regulators and coreceptors that are physically associated with MET either at the cell surface or intracytoplasmic domain that might consequently induce MET transactivation (15).”
BackgroundPapillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors.
Delahunt, B., & Eble, J. N. (1997) · PubMed · Cited by 714
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497 · cited 2×
“938) Damaging (0) (9, 10, 11, 25) 17 3476C>G S1159W S1141W Somatic Probably damaging (1) Damaging (0) — 17 3538C>T H1180Y H1162Y ND Probably damaging (0.”
Background
Cited by
MET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 323
Pal, S. K., Tangen, C., Thompson, I. M., Balzer-Haas, N., George, D. J., Heng, D. Y. C., Shuch, B., Stein, M., Tretiakova, M., Humphrey, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00152-5 · Cited by 287
Choueiri, T. K., Heng, D. Y. C., Lee, J. L., Cancel, M., Verheijen, R. B., Mellemgaard, A., Ottesen, L. H., Frigault, M. M., L’Hernault, A., Szijgyarto, Z., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2218 · Cited by 177
Self-citation
Metadata
- Authors
- Albiges, L., Guegan, J., Le Formal, A., Verkarre, V., Rioux-Leclercq, N., Sibony, M., Bernhard, J.-C., Camparo, P., Merabet, Z., Molinie, V., Allory, Y., Orear, C., Couvé, S., Gad, S., Patard, J.-J., & Escudier, B.
- Venue
- Clinical Cancer Research
- Published
- 2014-06-30
- Volume
- 20
- Issue
- 13
- Pages
- 3411-3421
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2146810218
- Cited by
- 176
- References
- 36
- FWCI
- 14.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2173
- The paper
- Albiges, L., Guegan, J., Le Formal, A., Verkarre, V., Rioux-Leclercq, N., Sibony, M., Bernhard, J.-C., Camparo, P., Merabet, Z., Molinie, V., Allory, Y., Orear, C., Couvé, S., Gad, S., Patard, J.-J., & Escudier, B. (2014). MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.